Physician profile
Xiang Hon Lin
NPI 1578520771
$3,077.38
in general payments reported to CMS, 2019-2025
22 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $760 · 2021: $534 · 2022: $435 · 2023: $145 · 2024: $184 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.81 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $363.14 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $360.27 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $307.02 | 2019-2022 | |
| Gilead Sciences, INC. | $240.49 | 2019-2021 | |
| Abbvie INC. | $234.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $203.64 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $167.97 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.06 | 2022 | |
| Verona Pharma, INC. | $67.45 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $67.33 | 2020-2025 | Rybelsus, Ozempic |
| Corium, LLC | $58.51 | 2022-2023 | Adlarity |
| Radius Health, INC. | $51.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $48.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.95 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44.62 | 2024 | Dupixent |
| Allergan, INC. | $39.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.81 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.19 | 2022 | |
| Boston Scientific Corporation | $25.97 | 2022 | |
| Alk-Abello, INC | $17.67 | 2024 | Grastek, Odactra, Ragwitek |
| Bayer Healthcare Pharmaceuticals INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiang Hon Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.